IBA SA : Strategic review of IBA Dosimetry business
Strategic review of IBA Dosimetry business
Louvain-la-Neuve, Belgium, July 20, 2018 - IBA (Ion Beam Applications S.A., EURONEXT), the world's leading provider of solutions for the diagnosis and treatment of cancer, today announces a strategic review of its Dosimetry business. The company is reviewing strategic alternatives for IBA Dosimetry, including a sale, merger, initial public offering, or retention of the business, and will provide an update on its plans by the end of the year.
Olivier Legrain, Chief Executive Officer of IBA, commented: "IBA Dosimetry saw strong growth in 2017. We are pleased that this growth now enables IBA to explore options to maximize the future value and strategic potential of this business. This review is in line with our stated aim to focus on our core proton therapy and other accelerators business and invest in technology, most specifically software. This will enable the company to further capitalize on the growth prospects and build on its market leading position in the global proton therapy market."
IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA's proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,500 people worldwide, IBA has installed systems across the world.
IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).
More information can be found at www.iba-worldwide.com
For further information, please contact:
Chief Financial Officer
+32 10 475 890
Global Marketing Proton Therapy and Communication Director
+32 10 475 890
For media and investor enquiries:
Consilium Strategic Communications
Amber Fennell, Matthew Neal
+44 (0) 20 3709 5700